Jeff Fuller1,2, Tanis C Dingle3,4, Amy Bull3, Sandy Shokoples3, Michel Laverdière5, Melanie R Baxter6, Heather J Adam6,7, James A Karlowsky6,7, George G Zhanel6. 1. Department of Pathology and Laboratory Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada. 2. Division of Microbiology, London Health Sciences Centre, 800 Commissioners Road E, London, Ontario, Canada. 3. Provincial Laboratory, Alberta Health Services, 8440-112 Street, Edmonton, Alberta, Canada. 4. Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada. 5. Department of Medicine, Microbiology and Infectious Diseases, Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada. 6. Department of Medical Microbiology/Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Room 543-745 Bannatyne Avenue, Winnipeg, Manitoba, Canada. 7. Clinical Microbiology, Diagnostic Services Manitoba, MS673-820 Sherbrook Street, Winnipeg, Manitoba, Canada.
Abstract
OBJECTIVES: Understanding the epidemiology of invasive Candida infections is essential to patient management decisions and antifungal stewardship practices. This study characterized the species distribution and antifungal susceptibilities of prospectively collected isolates of Candida species causing bloodstream infections (BSIs) in patients admitted to tertiary care hospitals located in 14 cities across 8 of the 10 Canadian provinces between 2011 and 2016. METHODS: Antifungal susceptibility testing was performed by broth microdilution using CLSI methods, breakpoints and epidemiological cut-off values. DNA sequencing of fks loci was performed on all echinocandin-non-susceptible isolates. RESULTS: Candida albicans (49.6%), Candida glabrata (20.8%) and Candida parapsilosis complex (12.0%) were the most common species out of 1882 isolates associated with BSIs. Candida tropicalis (5.2%), Candida krusei (4.3%), Candida dubliniensis (4.1%), Candida lusitaniae (1.4%) and Candida guilliermondii (1.1%) were less frequently isolated. Between 2011 and 2016, the proportion of C. albicans significantly decreased from 60.9% to 42.1% (P < 0.0001) while that of C. glabrata significantly increased from 16.4% to 22.4% (P = 0.023). C. albicans (n = 934), C. glabrata (n = 392) and C. parapsilosis complex (n = 225) exhibited 0.6%, 1.0% and 4.9% resistance to fluconazole and 0.1%, 2.5% and 0% resistance to micafungin, respectively. Mutations in fks hot-spot regions were confirmed in all nine micafungin non-susceptible C. glabrata. CONCLUSIONS: Antifungal resistance in contemporary isolates of Candida causing BSIs in Canada is uncommon. However, the proportion of C. glabrata isolates has increased and echinocandin resistance in this species has emerged. Ongoing surveillance of local hospital epidemiology and appropriate antifungal stewardship practices are necessary to preserve the utility of available antifungal agents.
OBJECTIVES: Understanding the epidemiology of invasive Candida infections is essential to patient management decisions and antifungal stewardship practices. This study characterized the species distribution and antifungal susceptibilities of prospectively collected isolates of Candida species causing bloodstream infections (BSIs) in patients admitted to tertiary care hospitals located in 14 cities across 8 of the 10 Canadian provinces between 2011 and 2016. METHODS: Antifungal susceptibility testing was performed by broth microdilution using CLSI methods, breakpoints and epidemiological cut-off values. DNA sequencing of fks loci was performed on all echinocandin-non-susceptible isolates. RESULTS:Candida albicans (49.6%), Candida glabrata (20.8%) and Candida parapsilosis complex (12.0%) were the most common species out of 1882 isolates associated with BSIs. Candida tropicalis (5.2%), Candida krusei (4.3%), Candida dubliniensis (4.1%), Candida lusitaniae (1.4%) and Candida guilliermondii (1.1%) were less frequently isolated. Between 2011 and 2016, the proportion of C. albicans significantly decreased from 60.9% to 42.1% (P < 0.0001) while that of C. glabrata significantly increased from 16.4% to 22.4% (P = 0.023). C. albicans (n = 934), C. glabrata (n = 392) and C. parapsilosis complex (n = 225) exhibited 0.6%, 1.0% and 4.9% resistance to fluconazole and 0.1%, 2.5% and 0% resistance to micafungin, respectively. Mutations in fks hot-spot regions were confirmed in all nine micafungin non-susceptible C. glabrata. CONCLUSIONS: Antifungal resistance in contemporary isolates of Candida causing BSIs in Canada is uncommon. However, the proportion of C. glabrata isolates has increased and echinocandin resistance in this species has emerged. Ongoing surveillance of local hospital epidemiology and appropriate antifungal stewardship practices are necessary to preserve the utility of available antifungal agents.
Authors: Guillermo Quindós; Katherine Miranda-Cadena; Rosario San-Millán; Katyna Borroto-Esoda; Emilia Cantón; María José Linares-Sicilia; Axel Hamprecht; Isabel Montesinos; Anna Maria Tortorano; Anna Prigitano; Matxalen Vidal-García; Cristina Marcos-Arias; Andrea Guridi; Ferran Sanchez-Reus; Jesús Machuca-Bárcena; Manuel Antonio Rodríguez-Iglesias; Estrella Martín-Mazuelos; Carmen Castro-Méndez; Leyre López-Soria; Alba Ruiz-Gaitán; Marcelo Fernandez-Rivero; Damaris Lorenzo; Javier Capilla; Antonio Rezusta; Javier Pemán; Josep Guarro; Joana Pereira; Célia Pais; Orazio Romeo; Guillermo Ezpeleta; Nerea Jauregizar; David Angulo; Elena Eraso Journal: Front Cell Infect Microbiol Date: 2022-05-16 Impact factor: 6.073
Authors: A T Coste; A Kritikos; J Li; N Khanna; D Goldenberger; C Garzoni; C Zehnder; K Boggian; D Neofytos; A Riat; D Bachmann; D Sanglard; F Lamoth Journal: Infection Date: 2020-07-13 Impact factor: 3.553
Authors: Sayed E El-Sayed; Neveen A Abdelaziz; Hosam-Eldin Hussein Osman; Ghadir S El-Housseiny; Ahmed E Aleissawy; Khaled M Aboshanab Journal: Molecules Date: 2021-12-29 Impact factor: 4.411